Skip to main content
Key Specialties
Anesthesiology Cardiology Dermatology Diabetology Endocrinology Gastroenterology General Medicine Geriatrics Hematology Infectious Diseases Internal Medicine Nephrology Neurology Obstetrics and Gynecology Oncology Ophthalmology Pediatrics Psychiatry Radiology Respiratory Medicine Rheumatology Surgery Urology
Congress Coverage
ASH 2024 Annual Meeting 2024 ESMO Congress 2024 ERS Congress 2024 EASD Congress 2024 ESC Congress 2024 EAN Congress 2024 ASCO Annual Meeting 2024 ACC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on adolescent vaping

LIVE: Wednesday 29th January, 18:00-19:30 CET

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?
ADVANCED SEARCH
Log in
Top
Digestive Diseases and Sciences

Open Access 08-01-2025 | Type 2 Diabetes | Original Article

From Endoscopic Inspection to Gene-Expression: A Thorough Assessment of the Duodenal Mucosa After Resurfacing—A Prospective Study

Authors: S. Meiring, Ö. Aydin, A. C. G. van Baar, E. W. J. van der Vossen, E. Rampanelli, N. C. T. van Grieken, F. Holleman, M. Nieuwdorp, J. J. G. H. M. Bergman

Published in: Digestive Diseases and Sciences

Login to get access

Abstract

Aims

Duodenal Mucosal Resurfacing (DMR) is an endoscopic ablation technique aimed at improving glycemia in patients with type 2 diabetes mellitus (T2DM). Although the exact underlying mechanism is still unclear, it is postulated that the DMR-induced improvements are the result of changes in the duodenal mucosa. For this reason, we assessed macroscopic and microscopic changes in the duodenal mucosa induced by DMR + GLP-1RA.

Methods

We included 16 patients with T2DM using basal insulin that received a combination treatment of a single DMR and GLP-1RA. Endoscopic evaluation was performed before the DMR procedure and 3 month after, and duodenal biopsies were obtained. Histological evaluation was performed and L and K cell density was calculated. In addition, gene-expression analysis and Western blotting was performed.

Results

Endoscopic evaluation at 3 month showed duodenal mucosa with a normal appearance. In line, microscopic histological evaluation showed no signs of villous atrophy or inflammation and unchanged L and K cell density. Unbiased transcriptome profiling and western blotting revealed that PDZK1 expression was higher in responders at baseline and after DMR. GATA6 expression was significantly increased in responders after DMR compared to non-responders.

Conclusion

The absence of macroscopic and microscopic changes after 3 month suggest that improvements in glycemic parameters after DMR do not result from significant histological changes in duodenal mucosa. It is more likely that these improvements result from more subtle changes in enteroendocrine signaling. PDZK1 and GATA6 expression might play a role in DMR; this needs to be confirmed in pre-clinical studies.
Appendix
Available only for authorised users
Literature
1.
2.
Mingrone G, Panunzi S, De Gaetano A et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet 2015;386:964–973.CrossRefPubMed
3.
Pendyala S, Walker JM, Holt PR. A high-fat diet is associated with endotoxemia that originates from the gut. Gastroenterology 2012;142:e2.CrossRef
4.
Cani PD, Amar J, Iglesias MA et al. Metabolic endotoxemia initiates obesity and insulin resistance. Diabetes 2007;56:1761–1772.CrossRefPubMed
5.
van Baar ACG, Nieuwdorp M, Holleman F et al. The Duodenum harbors a Broad Untapped Therapeutic Potential. Gastroenterology 2018;154:773–777.CrossRefPubMed
6.
Nauck MA, Bartels E, Orskov C et al. Additive insulinotropic effects of exogenous synthetic human gastric inhibitory polypeptide and glucagon-like peptide-1-(7–36) amide infused at near-physiological insulinotropic hormone and glucose concentrations. J Clin Endocrinol Metab 1993;76:912–917.PubMed
7.
Meier JJ, Gallwitz B, Siepmann N et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycaemia. Diabetologia 2003;46:798–801.CrossRefPubMed
8.
Elrick H, Stimmler L, Hlad CJ Jr et al. Plasma Insulin Response to Oral and Intravenous Glucose Administration. J Clin Endocrinol Metab 1964;24:1076–1082.CrossRefPubMed
9.
Turton MD, O’Shea D, Gunn I et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996;379:69–72.CrossRefPubMed
10.
11.
N. van Olst SMea. Small intestinall physiology relevant to bariatric and metabolic endoscopic therapies: Incretins, bile acid signalling, and gut microbiome Volume 22. Techniques and Innovations Gastrointestinal Endoscopy 2020:109–119.
12.
Van der Schueren BJ, Homel P, Alam M et al. Magnitude and variability of the glucagon-like peptide-1 response in patients with type 2 diabetes up to 2 years following gastric bypass surgery. Diabetes Care 2012;35:42–46.CrossRefPubMed
13.
Holter MM, Dutia R, Stano SM et al. Glucose Metabolism After Gastric Banding and Gastric Bypass in Individuals With Type 2 Diabetes: Weight Loss Effect. Diabetes Care 2017;40:7–15.CrossRefPubMed
14.
Lund MT, Hansen M, Skaaby S et al. Preoperative beta-cell function in patients with type 2 diabetes is important for the outcome of Roux-en-Y gastric bypass surgery. J Physiol 2015;593:3123–3133.CrossRefPubMedPubMedCentral
15.
Laferrere B, Teixeira J, McGinty J et al. Effect of weight loss by gastric bypass surgery versus hypocaloric diet on glucose and incretin levels in patients with type 2 diabetes. J Clin Endocrinol Metab 2008;93:2479–2485.CrossRefPubMedPubMedCentral
16.
Purnell JQ, Johnson GS, Wahed AS et al. Prospective evaluation of insulin and incretin dynamics in obese adults with and without diabetes for 2 years after Roux-en-Y gastric bypass. Diabetologia 2018;61:1142–1154.CrossRefPubMedPubMedCentral
17.
Rajagopalan H, Cherrington AD, Thompson CC et al. Endoscopic Duodenal Mucosal Resurfacing for the Treatment of Type 2 Diabetes: 6-Month Interim Analysis From the First-in-Human Proof-of-Concept Study. Diabetes Care 2016;39:2254–2261.CrossRefPubMed
18.
van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus: one year results from the first international, open-label, prospective, multicentre study. Gut 2019.
19.
Bergman J, Deviere J, Hopkins D. Abstract: Topline results from REVITA-2: The first randomized, double-blind, sham-controlled, prospective, multicenter study of duodenal mucosal resurfacing (DMR) efficacy, safety, and impact on NASH biomarkers in T2D: American Association for the Study of Liver Diseases 2019.
20.
McDermaid A, Monier B, Zhao J et al. Interpretation of differential gene expression results of RNA-seq data: review and integration. Brief Bioinform 2019;20:2044–2054.CrossRefPubMed
21.
22.
van Baar ACG, Meiring S, Smeele P, et al. Duodenal mucosal resurfacing combined with GLP-1RA to discontinue insulin in type 2 diabetes: a feasibility study. Gastrointest Endosc 2020.
23.
Hewitson TD. Histology Protocols In: Darby IA, ed: Humana Press, 2010.
24.
Mingrone G, van Baar AC, Deviere J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2 diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut 2021.
25.
26.
Tofe S, Arguelles I, Mena E et al. Real-world GLP-1 RA therapy in type 2 diabetes: A long-term effectiveness observational study. Endocrinol Diabetes Metab 2019;2:e00051.CrossRefPubMed
27.
28.
29.
Udayappan SD, Kovatcheva-Datchary P, Bakker GJ et al. Intestinal Ralstonia pickettii augments glucose intolerance in obesity. PLoS One 2017;12:e0181693.CrossRefPubMedPubMedCentral
30.
Maassen JA, Romijn JA, Heine RJ. Fatty acid-induced mitochondrial uncoupling in adipocytes as a key protective factor against insulin resistance and beta cell dysfunction: a new concept in the pathogenesis of obesity-associated type 2 diabetes mellitus. Diabetologia 2007;50:2036–2041.CrossRefPubMedPubMedCentral
31.
Bakker GJ, Meijnikman AS, Scheithauer TP et al. Fecal microbiota transplantation does not alter bacterial translocation and visceral adipose tissue inflammation in individuals with obesity. Obes Sci Pract 2022;8:56–65.CrossRefPubMed
32.
Metadata
Title
From Endoscopic Inspection to Gene-Expression: A Thorough Assessment of the Duodenal Mucosa After Resurfacing—A Prospective Study
Authors
S. Meiring
Ö. Aydin
A. C. G. van Baar
E. W. J. van der Vossen
E. Rampanelli
N. C. T. van Grieken
F. Holleman
M. Nieuwdorp
J. J. G. H. M. Bergman
Publication date
08-01-2025
Publisher
Springer US
Published in
Digestive Diseases and Sciences
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-024-08710-4

Keynote webinar | Spotlight on menopause

Menopause can have a significant impact on the body, with effects ranging beyond the endocrine and reproductive systems. Learn about the broader systemic effects of menopause, so you can help patients in your clinics through the transition.   

Prof. Martha Hickey
Dr. Claudia Barth
Dr. Samar El Khoudary
Developed by: Springer Medicine
Watch now

Keynote webinar | Spotlight on adolescent vaping

  • Live
  • Webinar | 29-01-2025 | 18:00 (CET)

Growing numbers of young people are using e-cigarettes, despite warnings of respiratory effects and addiction. How can doctors tackle the epidemic, and what health effects should you prepare to manage in your clinics?

Watch it live: Wednesday 29th January, 18:00-19:30 CET
 

Prof. Ann McNeill
Dr. Debbie Robson
Benji Horwell
Developed by: Springer Medicine
Join the webinar

Keynote webinar | Spotlight on modern management of frailty

Frailty has a significant impact on health and wellbeing, especially in older adults. Our experts explain the factors that contribute to the development of frailty and how you can manage the condition and reduce the risk of disability, dependency, and mortality in your patients.

Prof. Alfonso Cruz-Jentoft
Prof. Barbara C. van Munster
Prof. Mirko Petrovic
Developed by: Springer Medicine
Watch now

A quick guide to ECGs

Improve your ECG interpretation skills with this comprehensive, rapid, interactive course. Expert advice provides detailed feedback as you work through 50 ECGs covering the most common cardiac presentations to ensure your practice stays up to date. 

PD Dr. Carsten W. Israel
Developed by: Springer Medizin
Start the cases

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Read more
Image Credits